Sofosbuvir
- Generic Name
- Sofosbuvir
- Brand Names
- Epclusa, Harvoni, Sovaldi, Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FN3O9P
- CAS Number
- 1190307-88-0
- Unique Ingredient Identifier
- WJ6CA3ZU8B
- Background
Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, ...
- Indication
Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 2, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT03549832
- Locations
- 🇪🇬
Assiut University Hopsital, Assiut, Egypt
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
- Conditions
- Interventions
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT03487848
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 150
- Registration Number
- NCT03480932
- Locations
- 🇮🇳
YR Gaitonde Centre for AIDS Education and Johns Hopkins University Collaborative Integrated Care Center (YRG-JHU ICC), Bilaspur, Chhattisgarh, India
Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Kawin Technology Share-holding Co., Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT03453346
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Chinese PLA 302 Hospital, Beijing, Beijing, China
🇨🇳Capital Medical University Affiliated Beijing You'an Hospital, Beijing, Beijing, China
Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Kawin Technology Share-holding Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT03416491
- Locations
- 🇨🇳
Chinese PLA Third Military Medical University First Affiliated Hospital, Chongqing, Chongqing, China
🇨🇳Dalian Municipal Sixth People's Hospital, Dalian, Liaoning, China
🇨🇳Jilin University First Hospital, Changchun, Jilin, China
HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 10
- Registration Number
- NCT03282474
- Locations
- 🇩🇪
Charité, Campus Virchow-Klinikum, Medical Department, Division of Hepatology and Gastroenterology, Berlin, Germany
🇩🇪University Medical Center Hamburg-Eppendorf, Center for Internal Medicine, I. Medical Clinic and Polyclinic, Hamburg, Germany
🇩🇪Hannover Medical School, Clinic for Gastroenterology, Hepatology, and Endocrinology, Hanover, Lower Saxony, Germany
A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Registration Number
- NCT03105349
- Locations
- 🇪🇸
Hospital Infanta Leonor, Madrid, Spain
🇪🇸Hospital Univ. Gregorio Marañon, Madrid, Spain
🇪🇸Hospital Univ. La Paz, Madrid, Spain
Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 10000
- Registration Number
- NCT02992457
- Locations
- 🇪🇬
Tanta university hospital, Tanta, Egypt
🇪🇬Sherief Abd-Elsalam, Tanta, Egypt
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 33
- Registration Number
- NCT02939989
- Locations
- 🇺🇸
Ruane Clinical Research Group /ID# 155714, Los Angeles, California, United States
🇨🇳Beijing Di Tan Hospital, Capital Medical University /ID# 218496, Beijing, China
🇨🇦University of Calgary /ID# 155726, Calgary, Alberta, Canada
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 2033
- Registration Number
- NCT02907996
- Locations
- 🇰🇷
Yonsei University Wonju Severance Christian Hospital, Wonju, Gangwon-do, Korea, Republic of
🇰🇷SoonChunHyang University Cheonan Hospital, Cheonan, Korea, Republic of
🇰🇷Daegu Catholic University Medical Center, Daegu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.